A Phase IIa, Single Blind, Randomized, Study to Evaluate the Safety, the Immunogenicity, and the Clinical and Biological Efficacy of IFNα-Kinoid (IFN-K) in Adult Subjects With Dermatomyositis
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Interferon alpha kinoid (Primary) ; Montanide ISA-51
- Indications Dermatomyositis
- Focus Pharmacodynamics; Proof of concept
- Sponsors Neovacs
- 31 Dec 2019 Status changed from active, no longer recruiting to discontinued.
- 23 Sep 2019 Status changed from recruiting to active, no longer recruiting.
- 20 Mar 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2020.